Login / Signup

Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.

Wayne GulliverAfsaneh AlaviMarni C WisemanMelinda J GooderhamJaggi RaoMaryam Shayesteh AlamKim A PappOlivier DesjardinsChristine Jean
Published in: Journal of cutaneous medicine and surgery (2022)
At week 24 and maintained at week 52 in a real-world setting, adalimumab meaningfully improved HRQoL, work productivity, and activity impairment in moderate-to-severe HS patients.
Keyphrases